Adage Capital Partners Gp, L.L.C. Intercept Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$12.53 - $21.71 $5.49 Million - $9.52 Million	438,437 New	438,437 $5.89 Million
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $610,500 - $985,000	50,000 New	50,000 $698,000
Q2 2022 Aug 15, 2022	SELL	$11.23 - $19.59 $1.12 Million - $1.96 Million	-100,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $15.1 Million - $20.2 Million	-1,133,000 Reduced 91.89%	100,000 $1.63 Million
Q4 2021 Feb 14, 2022	BUY	$14.28 - $19.53 $17.6 Million - $24.1 Million	1,233,000 New	1,233,000 $20.1 Million
Q3 2020 Nov 16, 2020	SELL	$39.09 - $53.44 $21.5 Million - $29.4 Million	-550,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$46.7 - $92.04 $25.7 Million - $50.6 Million	550,000 New	550,000 $26.4 Million
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $19.5 Million - $26.8 Million	-333,100 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$77.77 - $120.68 $13.4 Million - $20.7 Million	-171,900 Reduced 34.04%	333,100 $26.5 Million
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $33.7 Million - $44.3 Million	367,000 Added 265.94%	505,000 $56.5 Million
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $11.8 Million - $17.5 Million	138,000 New	138,000 $13.9 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.